PMCID	SUBJECT_SCOPE_ID	S_START	S_END	SUBJECT_SCOPE	CONCEPT	IGNORANCE TYPE	C_START	C_END	CONCEPT_MENTION_ID
PMC1252725	PMC1252725_0	[0]	[324]	['Evaluation of maternal infusion therapy during pregnancy for fetal development\n\nAbstract\nThe aim of this project was to study the possible association between maternal infusion treatments during pregnancy and variables of fetal development as well as the occurrence of congenital abnormalities (CA) in a case-control design.']	pregnancy	GO_BP	[47]	[56]	PMC1252725_T66
PMC1252725	PMC1252725_0	[0]	[324]	['Evaluation of maternal infusion therapy during pregnancy for fetal development\n\nAbstract\nThe aim of this project was to study the possible association between maternal infusion treatments during pregnancy and variables of fetal development as well as the occurrence of congenital abnormalities (CA) in a case-control design.']	fetal development	GO_BP	[61]	[78]	PMC1252725_T67
PMC1252725	PMC1252725_0	[0]	[324]	['Evaluation of maternal infusion therapy during pregnancy for fetal development\n\nAbstract\nThe aim of this project was to study the possible association between maternal infusion treatments during pregnancy and variables of fetal development as well as the occurrence of congenital abnormalities (CA) in a case-control design.']	pregnancy	GO_BP	[195]	[204]	PMC1252725_T68
PMC1252725	PMC1252725_0	[0]	[324]	['Evaluation of maternal infusion therapy during pregnancy for fetal development\n\nAbstract\nThe aim of this project was to study the possible association between maternal infusion treatments during pregnancy and variables of fetal development as well as the occurrence of congenital abnormalities (CA) in a case-control design.']	fetal development	GO_BP	[222]	[239]	PMC1252725_T69
PMC1252725	PMC1252725_1	[325]	[523]	['The large population-based data set of the Hungarian Case‑Control Surveillance of Congenital Abnormalities (HCCSCA) was evaluated based on the medically recorded infusion treatment during pregnancy.']	pregnancy	GO_BP	[513]	[522]	PMC1252725_T70
PMC1252725	PMC1252725_2	[524]	[761]	['Of 22,843 case pregnant women who had newborns or fetuses with congenital abnormalities, 112 (0.5%), while of 38,151 control pregnant women who had newborn infants without any defects, 262 (0.7%), had infusion treatment during pregnancy.']	pregnant	GO_BP	[539]	[547]	PMC1252725_T71
PMC1252725	PMC1252725_2	[524]	[761]	['Of 22,843 case pregnant women who had newborns or fetuses with congenital abnormalities, 112 (0.5%), while of 38,151 control pregnant women who had newborn infants without any defects, 262 (0.7%), had infusion treatment during pregnancy.']	pregnant	GO_BP	[649]	[657]	PMC1252725_T72
PMC1252725	PMC1252725_2	[524]	[761]	['Of 22,843 case pregnant women who had newborns or fetuses with congenital abnormalities, 112 (0.5%), while of 38,151 control pregnant women who had newborn infants without any defects, 262 (0.7%), had infusion treatment during pregnancy.']	pregnancy	GO_BP	[751]	[760]	PMC1252725_T73
PMC1252725	PMC1252725_4	[1016]	[1235]	['Mean gestational age was shorter and mean birth weight was smaller in control newborn infants without CA born to mothers with infusion treatment during pregnancy than in the babies of mothers without infusion treatment.']	gestational	GO_BP	[1021]	[1032]	PMC1252725_T74
PMC1252725	PMC1252725_4	[1016]	[1235]	['Mean gestational age was shorter and mean birth weight was smaller in control newborn infants without CA born to mothers with infusion treatment during pregnancy than in the babies of mothers without infusion treatment.']	birth	GO_BP	[1058]	[1063]	PMC1252725_T75
PMC1252725	PMC1252725_4	[1016]	[1235]	['Mean gestational age was shorter and mean birth weight was smaller in control newborn infants without CA born to mothers with infusion treatment during pregnancy than in the babies of mothers without infusion treatment.']	born	GO_BP	[1121]	[1125]	PMC1252725_T76
PMC1252725	PMC1252725_4	[1016]	[1235]	['Mean gestational age was shorter and mean birth weight was smaller in control newborn infants without CA born to mothers with infusion treatment during pregnancy than in the babies of mothers without infusion treatment.']	pregnancy	GO_BP	[1168]	[1177]	PMC1252725_T77
PMC1252725	PMC1252725_5	[1236]	[1392]	['The prevalence of mild intrauterine growth retardation was more frequent in the fetuses of pregnant women with hyperemesis gravidarum treated with infusion.']	intrauterine	UBERON	[1259]	[1271]	PMC1252725_T243
PMC1252725	PMC1252725_5	[1236]	[1392]	['The prevalence of mild intrauterine growth retardation was more frequent in the fetuses of pregnant women with hyperemesis gravidarum treated with infusion.']	pregnant	GO_BP	[1327]	[1335]	PMC1252725_T78
PMC1252725	PMC1252725_5	[1236]	[1392]	['The prevalence of mild intrauterine growth retardation was more frequent in the fetuses of pregnant women with hyperemesis gravidarum treated with infusion.']	hyperemesis	GO_BP	[1347]	[1358]	PMC1252725_T79
PMC1252725	PMC1252725_6	[1393]	[1533]	['The results of the study suggest that infusion treatment of pregnant women did not associate with a higher risk of congenital abnormalities.']	pregnant	GO_BP	[1453]	[1461]	PMC1252725_T80
PMC1252725	PMC1252725_7	[1534]	[1701]	['In addition, the intravenous infusion of drugs has some, but limited efficacy to prevent the adverse effects of hyperemesis gravidarum and threatened preterm delivery.']	drugs	CHEBI	[1575]	[1580]	PMC1252725_T0
PMC1252725	PMC1252725_7	[1534]	[1701]	['In addition, the intravenous infusion of drugs has some, but limited efficacy to prevent the adverse effects of hyperemesis gravidarum and threatened preterm delivery.']	hyperemesis	GO_BP	[1646]	[1657]	PMC1252725_T81
PMC1252725	PMC1252725_7	[1534]	[1701]	['In addition, the intravenous infusion of drugs has some, but limited efficacy to prevent the adverse effects of hyperemesis gravidarum and threatened preterm delivery.']	preterm	GO_BP	[1684]	[1691]	PMC1252725_T82
PMC1252725	PMC1252725_7	[1534]	[1701]	['In addition, the intravenous infusion of drugs has some, but limited efficacy to prevent the adverse effects of hyperemesis gravidarum and threatened preterm delivery.']	delivery	GO_BP	[1692]	[1700]	PMC1252725_T83
PMC1252725	PMC1252725_9	[1706]	[2096]	['Introduction\nThe effect of drugs during pregnancy is determined beyond the chemical structure of product, the treatment time during gestation, dose, duration of treatment, underlying diseases and pregnancy complications, other drugs due to their possible interaction and last but not least the type of administration: oral, rectal, vaginal, ophthalmic, otic, nasal, topical and parenteral1.']	drugs	CHEBI	[1733]	[1738]	PMC1252725_T1
PMC1252725	PMC1252725_9	[1706]	[2096]	['Introduction\nThe effect of drugs during pregnancy is determined beyond the chemical structure of product, the treatment time during gestation, dose, duration of treatment, underlying diseases and pregnancy complications, other drugs due to their possible interaction and last but not least the type of administration: oral, rectal, vaginal, ophthalmic, otic, nasal, topical and parenteral1.']	pregnancy	GO_BP	[1746]	[1755]	PMC1252725_T84
PMC1252725	PMC1252725_9	[1706]	[2096]	['Introduction\nThe effect of drugs during pregnancy is determined beyond the chemical structure of product, the treatment time during gestation, dose, duration of treatment, underlying diseases and pregnancy complications, other drugs due to their possible interaction and last but not least the type of administration: oral, rectal, vaginal, ophthalmic, otic, nasal, topical and parenteral1.']	gestation	GO_BP	[1838]	[1847]	PMC1252725_T85
PMC1252725	PMC1252725_9	[1706]	[2096]	['Introduction\nThe effect of drugs during pregnancy is determined beyond the chemical structure of product, the treatment time during gestation, dose, duration of treatment, underlying diseases and pregnancy complications, other drugs due to their possible interaction and last but not least the type of administration: oral, rectal, vaginal, ophthalmic, otic, nasal, topical and parenteral1.']	pregnancy	GO_BP	[1902]	[1911]	PMC1252725_T86
PMC1252725	PMC1252725_9	[1706]	[2096]	['Introduction\nThe effect of drugs during pregnancy is determined beyond the chemical structure of product, the treatment time during gestation, dose, duration of treatment, underlying diseases and pregnancy complications, other drugs due to their possible interaction and last but not least the type of administration: oral, rectal, vaginal, ophthalmic, otic, nasal, topical and parenteral1.']	drugs	CHEBI	[1933]	[1938]	PMC1252725_T2
PMC1252725	PMC1252725_9	[1706]	[2096]	['Introduction\nThe effect of drugs during pregnancy is determined beyond the chemical structure of product, the treatment time during gestation, dose, duration of treatment, underlying diseases and pregnancy complications, other drugs due to their possible interaction and last but not least the type of administration: oral, rectal, vaginal, ophthalmic, otic, nasal, topical and parenteral1.']	oral	UBERON	[2024]	[2028]	PMC1252725_T244
PMC1252725	PMC1252725_9	[1706]	[2096]	['Introduction\nThe effect of drugs during pregnancy is determined beyond the chemical structure of product, the treatment time during gestation, dose, duration of treatment, underlying diseases and pregnancy complications, other drugs due to their possible interaction and last but not least the type of administration: oral, rectal, vaginal, ophthalmic, otic, nasal, topical and parenteral1.']	rectal	UBERON	[2030]	[2036]	PMC1252725_T245
PMC1252725	PMC1252725_9	[1706]	[2096]	['Introduction\nThe effect of drugs during pregnancy is determined beyond the chemical structure of product, the treatment time during gestation, dose, duration of treatment, underlying diseases and pregnancy complications, other drugs due to their possible interaction and last but not least the type of administration: oral, rectal, vaginal, ophthalmic, otic, nasal, topical and parenteral1.']	vaginal	UBERON	[2038]	[2045]	PMC1252725_T246
PMC1252725	PMC1252725_9	[1706]	[2096]	['Introduction\nThe effect of drugs during pregnancy is determined beyond the chemical structure of product, the treatment time during gestation, dose, duration of treatment, underlying diseases and pregnancy complications, other drugs due to their possible interaction and last but not least the type of administration: oral, rectal, vaginal, ophthalmic, otic, nasal, topical and parenteral1.']	ophthalmic	UBERON	[2047]	[2057]	PMC1252725_T247
PMC1252725	PMC1252725_9	[1706]	[2096]	['Introduction\nThe effect of drugs during pregnancy is determined beyond the chemical structure of product, the treatment time during gestation, dose, duration of treatment, underlying diseases and pregnancy complications, other drugs due to their possible interaction and last but not least the type of administration: oral, rectal, vaginal, ophthalmic, otic, nasal, topical and parenteral1.']	nasal	UBERON	[2065]	[2070]	PMC1252725_T248
PMC1252725	PMC1252725_10	[2097]	[2201]	['Among parenteral medications, subcutaneous, intramuscular and intravenous routes can be differentiated2.']	medications	CHEBI	[2114]	[2125]	PMC1252725_T3
PMC1252725	PMC1252725_11	[2202]	[2322]	['In the latter some drugs are administered at once or by slow push, and continuous or intermittent intravenous infusion3.']	drugs	CHEBI	[2221]	[2226]	PMC1252725_T4
PMC1252725	PMC1252725_12	[2323]	[2593]	['Clinical studies have shown that intravenous infusion of certain drugs is more effective than other administrations due to immediate drug action4; in addition, intravenous fluids are used for many sick and injured patients to treat dehydration and loss of electrolytes5.']	drugs	CHEBI	[2388]	[2393]	PMC1252725_T5
PMC1252725	PMC1252725_12	[2323]	[2593]	['Clinical studies have shown that intravenous infusion of certain drugs is more effective than other administrations due to immediate drug action4; in addition, intravenous fluids are used for many sick and injured patients to treat dehydration and loss of electrolytes5.']	drug	CHEBI	[2456]	[2460]	PMC1252725_T6
PMC1252725	PMC1252725_12	[2323]	[2593]	['Clinical studies have shown that intravenous infusion of certain drugs is more effective than other administrations due to immediate drug action4; in addition, intravenous fluids are used for many sick and injured patients to treat dehydration and loss of electrolytes5.']	intravenous	UBERON	[2483]	[2494]	PMC1252725_T249
PMC1252725	PMC1252725_12	[2323]	[2593]	['Clinical studies have shown that intravenous infusion of certain drugs is more effective than other administrations due to immediate drug action4; in addition, intravenous fluids are used for many sick and injured patients to treat dehydration and loss of electrolytes5.']	fluids	CHEBI	[2495]	[2501]	PMC1252725_T7
PMC1252725	PMC1252725_12	[2323]	[2593]	['Clinical studies have shown that intravenous infusion of certain drugs is more effective than other administrations due to immediate drug action4; in addition, intravenous fluids are used for many sick and injured patients to treat dehydration and loss of electrolytes5.']	fluids	UBERON	[2495]	[2501]	PMC1252725_T250
PMC1252725	PMC1252725_13	[2594]	[2892]	['Infusion treatment is also used in pregnant women particularly for prolonging pregnancy in women at risk for preterm delivery6, with extreme severe nausea-vomiting (the so-called hyperemesis gravidarum)7,8and after surgery large volumes of hypotonic fluid are generally given to pregnant women9,10.']	pregnant	GO_BP	[2629]	[2637]	PMC1252725_T87
PMC1252725	PMC1252725_13	[2594]	[2892]	['Infusion treatment is also used in pregnant women particularly for prolonging pregnancy in women at risk for preterm delivery6, with extreme severe nausea-vomiting (the so-called hyperemesis gravidarum)7,8and after surgery large volumes of hypotonic fluid are generally given to pregnant women9,10.']	pregnancy	GO_BP	[2672]	[2681]	PMC1252725_T88
PMC1252725	PMC1252725_13	[2594]	[2892]	['Infusion treatment is also used in pregnant women particularly for prolonging pregnancy in women at risk for preterm delivery6, with extreme severe nausea-vomiting (the so-called hyperemesis gravidarum)7,8and after surgery large volumes of hypotonic fluid are generally given to pregnant women9,10.']	preterm	GO_BP	[2703]	[2710]	PMC1252725_T89
PMC1252725	PMC1252725_13	[2594]	[2892]	['Infusion treatment is also used in pregnant women particularly for prolonging pregnancy in women at risk for preterm delivery6, with extreme severe nausea-vomiting (the so-called hyperemesis gravidarum)7,8and after surgery large volumes of hypotonic fluid are generally given to pregnant women9,10.']	delivery6	GO_BP	[2711]	[2720]	PMC1252725_T90
PMC1252725	PMC1252725_13	[2594]	[2892]	['Infusion treatment is also used in pregnant women particularly for prolonging pregnancy in women at risk for preterm delivery6, with extreme severe nausea-vomiting (the so-called hyperemesis gravidarum)7,8and after surgery large volumes of hypotonic fluid are generally given to pregnant women9,10.']	hyperemesis	GO_BP	[2773]	[2784]	PMC1252725_T91
PMC1252725	PMC1252725_13	[2594]	[2892]	['Infusion treatment is also used in pregnant women particularly for prolonging pregnancy in women at risk for preterm delivery6, with extreme severe nausea-vomiting (the so-called hyperemesis gravidarum)7,8and after surgery large volumes of hypotonic fluid are generally given to pregnant women9,10.']	fluid	UBERON	[2844]	[2849]	PMC1252725_T251
PMC1252725	PMC1252725_13	[2594]	[2892]	['Infusion treatment is also used in pregnant women particularly for prolonging pregnancy in women at risk for preterm delivery6, with extreme severe nausea-vomiting (the so-called hyperemesis gravidarum)7,8and after surgery large volumes of hypotonic fluid are generally given to pregnant women9,10.']	pregnant	GO_BP	[2873]	[2881]	PMC1252725_T92
PMC1252725	PMC1252725_14	[2893]	[3093]	['As Friedman and Polifka11stated, the effect of infusion treatments during pregnancy was rarely studied for fetal development, and only the effect of specific drugs used by infusion was evaluated12,13.']	pregnancy	GO_BP	[2967]	[2976]	PMC1252725_T93
PMC1252725	PMC1252725_14	[2893]	[3093]	['As Friedman and Polifka11stated, the effect of infusion treatments during pregnancy was rarely studied for fetal development, and only the effect of specific drugs used by infusion was evaluated12,13.']	fetal development	GO_BP	[3000]	[3017]	PMC1252725_T94
PMC1252725	PMC1252725_14	[2893]	[3093]	['As Friedman and Polifka11stated, the effect of infusion treatments during pregnancy was rarely studied for fetal development, and only the effect of specific drugs used by infusion was evaluated12,13.']	drugs	CHEBI	[3051]	[3056]	PMC1252725_T8
PMC1252725	PMC1252725_15	[3094]	[3567]	['The population-based large data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities (HCCSCA 1980-1996)14is ideal for us to check the possible association between maternal infusion therapy during pregnancy and the occurrence of congenital abnormalities (CAs), in addition to study gestational age, birth weight, the proportion of preterm birth and low birthweight in control newborn infants without CA born to mothers with or without infusion therapy.']	pregnancy	GO_BP	[3312]	[3321]	PMC1252725_T95
PMC1252725	PMC1252725_15	[3094]	[3567]	['The population-based large data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities (HCCSCA 1980-1996)14is ideal for us to check the possible association between maternal infusion therapy during pregnancy and the occurrence of congenital abnormalities (CAs), in addition to study gestational age, birth weight, the proportion of preterm birth and low birthweight in control newborn infants without CA born to mothers with or without infusion therapy.']	gestational	GO_BP	[3397]	[3408]	PMC1252725_T96
PMC1252725	PMC1252725_15	[3094]	[3567]	['The population-based large data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities (HCCSCA 1980-1996)14is ideal for us to check the possible association between maternal infusion therapy during pregnancy and the occurrence of congenital abnormalities (CAs), in addition to study gestational age, birth weight, the proportion of preterm birth and low birthweight in control newborn infants without CA born to mothers with or without infusion therapy.']	birth	GO_BP	[3414]	[3419]	PMC1252725_T97
PMC1252725	PMC1252725_15	[3094]	[3567]	['The population-based large data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities (HCCSCA 1980-1996)14is ideal for us to check the possible association between maternal infusion therapy during pregnancy and the occurrence of congenital abnormalities (CAs), in addition to study gestational age, birth weight, the proportion of preterm birth and low birthweight in control newborn infants without CA born to mothers with or without infusion therapy.']	preterm	GO_BP	[3446]	[3453]	PMC1252725_T98
PMC1252725	PMC1252725_15	[3094]	[3567]	['The population-based large data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities (HCCSCA 1980-1996)14is ideal for us to check the possible association between maternal infusion therapy during pregnancy and the occurrence of congenital abnormalities (CAs), in addition to study gestational age, birth weight, the proportion of preterm birth and low birthweight in control newborn infants without CA born to mothers with or without infusion therapy.']	birth	GO_BP	[3454]	[3459]	PMC1252725_T99
PMC1252725	PMC1252725_15	[3094]	[3567]	['The population-based large data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities (HCCSCA 1980-1996)14is ideal for us to check the possible association between maternal infusion therapy during pregnancy and the occurrence of congenital abnormalities (CAs), in addition to study gestational age, birth weight, the proportion of preterm birth and low birthweight in control newborn infants without CA born to mothers with or without infusion therapy.']	born	GO_BP	[3518]	[3522]	PMC1252725_T100
PMC1252725	PMC1252725_18	[3728]	[4083]	['Notification of cases with CAs is compulsory for physicians, and most are reported by obstetricians (in Hungary practically all deliveries occur in inpatient obstetric units and birth attendants are obstetricians) and paediatricians (who work in the neonatal units of inpatient obstetric clinics or in various inpatient and outpatient paediatric clinics).']	deliveries	GO_BP	[3856]	[3866]	PMC1252725_T101
PMC1252725	PMC1252725_18	[3728]	[4083]	['Notification of cases with CAs is compulsory for physicians, and most are reported by obstetricians (in Hungary practically all deliveries occur in inpatient obstetric units and birth attendants are obstetricians) and paediatricians (who work in the neonatal units of inpatient obstetric clinics or in various inpatient and outpatient paediatric clinics).']	birth	GO_BP	[3906]	[3911]	PMC1252725_T102
PMC1252725	PMC1252725_18	[3728]	[4083]	['Notification of cases with CAs is compulsory for physicians, and most are reported by obstetricians (in Hungary practically all deliveries occur in inpatient obstetric units and birth attendants are obstetricians) and paediatricians (who work in the neonatal units of inpatient obstetric clinics or in various inpatient and outpatient paediatric clinics).']	neonatal	UBERON	[3978]	[3986]	PMC1252725_T252
PMC1252725	PMC1252725_19	[4084]	[4184]	['Autopsy was obligatory for all infant deaths and usual in stillborn fetuses during the study period.']	deaths	GO_BP	[4122]	[4128]	PMC1252725_T103
PMC1252725	PMC1252725_20	[4185]	[4300]	['Pathologists sent a copy of autopsy report to the HCAR if defects were identified in stillbirths and infant deaths.']	stillbirths	GO_BP	[4270]	[4281]	PMC1252725_T104
PMC1252725	PMC1252725_20	[4185]	[4300]	['Pathologists sent a copy of autopsy report to the HCAR if defects were identified in stillbirths and infant deaths.']	deaths	GO_BP	[4293]	[4299]	PMC1252725_T105
PMC1252725	PMC1252725_21	[4301]	[4657]	['The recorded total prevalence of cases with CA diagnosed from the second trimester of pregnancies through the age of one year was 35 per 1000 informative offspring (liveborn infants, stillborn fetuses and electively terminated pregnancies due to malformed fetuses) and about 90% of major CAs were reported to the HCAR during 17 years of the study period15.']	trimester	GO_BP	[4374]	[4383]	PMC1252725_T106
PMC1252725	PMC1252725_21	[4301]	[4657]	['The recorded total prevalence of cases with CA diagnosed from the second trimester of pregnancies through the age of one year was 35 per 1000 informative offspring (liveborn infants, stillborn fetuses and electively terminated pregnancies due to malformed fetuses) and about 90% of major CAs were reported to the HCAR during 17 years of the study period15.']	pregnancies	GO_BP	[4387]	[4398]	PMC1252725_T107
PMC1252725	PMC1252725_21	[4301]	[4657]	['The recorded total prevalence of cases with CA diagnosed from the second trimester of pregnancies through the age of one year was 35 per 1000 informative offspring (liveborn infants, stillborn fetuses and electively terminated pregnancies due to malformed fetuses) and about 90% of major CAs were reported to the HCAR during 17 years of the study period15.']	pregnancies	GO_BP	[4528]	[4539]	PMC1252725_T108
PMC1252725	PMC1252725_23	[4728]	[4851]	['Firstly, only cases that were reported during the first three months after birth or termination of pregnancy were selected.']	birth	GO_BP	[4803]	[4808]	PMC1252725_T109
PMC1252725	PMC1252725_23	[4728]	[4851]	['Firstly, only cases that were reported during the first three months after birth or termination of pregnancy were selected.']	termination of pregnancy	GO_BP	[4812]	[4836]	PMC1252725_T110
PMC1252725	PMC1252725_24	[4852]	[5073]	['This shorter time between “pregnancy end” and data collection increases the accuracy of information about pregnancy history without undue loss of power since 77% of cases were reported during this time window to the HCAR.']	pregnancy	GO_BP	[4879]	[4888]	PMC1252725_T111
PMC1252725	PMC1252725_24	[4852]	[5073]	['This shorter time between “pregnancy end” and data collection increases the accuracy of information about pregnancy history without undue loss of power since 77% of cases were reported during this time window to the HCAR.']	pregnancy	GO_BP	[4958]	[4967]	PMC1252725_T112
PMC1252725	PMC1252725_25	[5074]	[5367]	['Secondly, three mild CAs (such as congenital dislocation of hip based on Ortolani click, congenital inguinal hernia, and large haemangioma), minor anomalies-variants (e.g., umbilical hernia, hydrocele, small haemangioma) and CA‑syndromes of known Mendelian or chromosomal origin were excluded.']	hip	UBERON	[5134]	[5137]	PMC1252725_T253
PMC1252725	PMC1252725_25	[5074]	[5367]	['Secondly, three mild CAs (such as congenital dislocation of hip based on Ortolani click, congenital inguinal hernia, and large haemangioma), minor anomalies-variants (e.g., umbilical hernia, hydrocele, small haemangioma) and CA‑syndromes of known Mendelian or chromosomal origin were excluded.']	Ortolani	CHEBI	[5147]	[5155]	PMC1252725_T9
PMC1252725	PMC1252725_25	[5074]	[5367]	['Secondly, three mild CAs (such as congenital dislocation of hip based on Ortolani click, congenital inguinal hernia, and large haemangioma), minor anomalies-variants (e.g., umbilical hernia, hydrocele, small haemangioma) and CA‑syndromes of known Mendelian or chromosomal origin were excluded.']	inguinal	UBERON	[5174]	[5182]	PMC1252725_T254
PMC1252725	PMC1252725_25	[5074]	[5367]	['Secondly, three mild CAs (such as congenital dislocation of hip based on Ortolani click, congenital inguinal hernia, and large haemangioma), minor anomalies-variants (e.g., umbilical hernia, hydrocele, small haemangioma) and CA‑syndromes of known Mendelian or chromosomal origin were excluded.']	umbilical	UBERON	[5247]	[5256]	PMC1252725_T255
PMC1252725	PMC1252725_26	[5369]	[5536]	['Controls\nControls were defined as newborn infants without CAs and they were selected from the National Birth Registry of the Central Statistical Office for the HCCSCA.']	Birth	GO_BP	[5472]	[5477]	PMC1252725_T113
PMC1252725	PMC1252725_27	[5537]	[5669]	["In general, two control newborn infants were matched to every case according to sex, birth week, and district of parents' residence."]	birth	GO_BP	[5622]	[5627]	PMC1252725_T114
PMC1252725	PMC1252725_29	[5815]	[6061]	['A post-paid questionnaire, explanatory letter along with a list of medicinal products (drugs and pregnancy supplements) and diseases, and a printed informed consent were mailed immediately after the selection of cases and controls to the mothers.']	drugs	CHEBI	[5902]	[5907]	PMC1252725_T10
PMC1252725	PMC1252725_29	[5815]	[6061]	['A post-paid questionnaire, explanatory letter along with a list of medicinal products (drugs and pregnancy supplements) and diseases, and a printed informed consent were mailed immediately after the selection of cases and controls to the mothers.']	pregnancy	GO_BP	[5912]	[5921]	PMC1252725_T115
PMC1252725	PMC1252725_30	[6062]	[6272]	['The questionnaire requested information, among others, on medicinal product intakes, pregnancy complications, maternal diseases and treatments including infusion during pregnancy according to gestational month.']	medicinal product	CHEBI	[6120]	[6137]	PMC1252725_T11
PMC1252725	PMC1252725_30	[6062]	[6272]	['The questionnaire requested information, among others, on medicinal product intakes, pregnancy complications, maternal diseases and treatments including infusion during pregnancy according to gestational month.']	pregnancy	GO_BP	[6147]	[6156]	PMC1252725_T116
PMC1252725	PMC1252725_30	[6062]	[6272]	['The questionnaire requested information, among others, on medicinal product intakes, pregnancy complications, maternal diseases and treatments including infusion during pregnancy according to gestational month.']	pregnancy	GO_BP	[6231]	[6240]	PMC1252725_T117
PMC1252725	PMC1252725_30	[6062]	[6272]	['The questionnaire requested information, among others, on medicinal product intakes, pregnancy complications, maternal diseases and treatments including infusion during pregnancy according to gestational month.']	gestational	GO_BP	[6254]	[6265]	PMC1252725_T118
PMC1252725	PMC1252725_31	[6273]	[6389]	['To standardize the answers, mothers were asked to read the enclosed lists of drugs and diseases before they replied.']	drugs	CHEBI	[6350]	[6355]	PMC1252725_T12
PMC1252725	PMC1252725_34	[6581]	[6773]	['Mothers were also asked to send us the antenatal care logbook and discharge summaries of hospitalisation during pregnancy together with the filled-in questionnaire and signed informed consent.']	antenatal care	GO_BP	[6620]	[6634]	PMC1252725_T119
PMC1252725	PMC1252725_34	[6581]	[6773]	['Mothers were also asked to send us the antenatal care logbook and discharge summaries of hospitalisation during pregnancy together with the filled-in questionnaire and signed informed consent.']	pregnancy	GO_BP	[6693]	[6702]	PMC1252725_T120
PMC1252725	PMC1252725_36	[6790]	[6945]	['time elapsed between the pregnancy end and return of the data package was 3.5 ± 1.2 and 5.2 ± 2.9 months in the groups of cases and controls, respectively.']	pregnancy	GO_BP	[6815]	[6824]	PMC1252725_T121
PMC1252725	PMC1252725_42	[7600]	[7695]	['Data from the antenatal care logbook were available in 88.4% of cases and in 93.8% of controls.']	antenatal care	GO_BP	[7614]	[7628]	PMC1252725_T122
PMC1252725	PMC1252725_49	[8076]	[8251]	['All infusion treatments were medically recorded in the discharge summary, because pregnant women with severe nausea-vomiting and threatened preterm delivery were hospitalized.']	pregnant	GO_BP	[8158]	[8166]	PMC1252725_T123
PMC1252725	PMC1252725_49	[8076]	[8251]	['All infusion treatments were medically recorded in the discharge summary, because pregnant women with severe nausea-vomiting and threatened preterm delivery were hospitalized.']	preterm	GO_BP	[8216]	[8223]	PMC1252725_T124
PMC1252725	PMC1252725_49	[8076]	[8251]	['All infusion treatments were medically recorded in the discharge summary, because pregnant women with severe nausea-vomiting and threatened preterm delivery were hospitalized.']	delivery	GO_BP	[8224]	[8232]	PMC1252725_T125
PMC1252725	PMC1252725_50	[8252]	[8315]	['Medication used through infusion and the intake of other drugs.']	drugs	CHEBI	[8309]	[8314]	PMC1252725_T13
PMC1252725	PMC1252725_51	[8316]	[8448]	['Pregnancy supplements (such as calcium, iron, and vitamins) and infusion used for labour induction were excluded from this analysis.']	Pregnancy	GO_BP	[8316]	[8325]	PMC1252725_T126
PMC1252725	PMC1252725_51	[8316]	[8448]	['Pregnancy supplements (such as calcium, iron, and vitamins) and infusion used for labour induction were excluded from this analysis.']	supplements	CHEBI	[8326]	[8337]	PMC1252725_T14
PMC1252725	PMC1252725_51	[8316]	[8448]	['Pregnancy supplements (such as calcium, iron, and vitamins) and infusion used for labour induction were excluded from this analysis.']	calcium	CHEBI	[8347]	[8354]	PMC1252725_T15
PMC1252725	PMC1252725_51	[8316]	[8448]	['Pregnancy supplements (such as calcium, iron, and vitamins) and infusion used for labour induction were excluded from this analysis.']	iron	CHEBI	[8356]	[8360]	PMC1252725_T16
PMC1252725	PMC1252725_51	[8316]	[8448]	['Pregnancy supplements (such as calcium, iron, and vitamins) and infusion used for labour induction were excluded from this analysis.']	vitamins	CHEBI	[8366]	[8374]	PMC1252725_T17
PMC1252725	PMC1252725_53	[8497]	[8861]	['Gestational age was calculated from the first day of last menstrual period and three time intervals were considered: (i) the first month of pregnancy, which is before organogenesis; (ii) the second and third months of gestation, considered the most sensitive, and the so-called critical period for most major CAs; and (iii) the fourth to ninth months of gestation.']	Gestational	GO_BP	[8497]	[8508]	PMC1252725_T127
PMC1252725	PMC1252725_53	[8497]	[8861]	['Gestational age was calculated from the first day of last menstrual period and three time intervals were considered: (i) the first month of pregnancy, which is before organogenesis; (ii) the second and third months of gestation, considered the most sensitive, and the so-called critical period for most major CAs; and (iii) the fourth to ninth months of gestation.']	pregnancy	GO_BP	[8637]	[8646]	PMC1252725_T128
PMC1252725	PMC1252725_53	[8497]	[8861]	['Gestational age was calculated from the first day of last menstrual period and three time intervals were considered: (i) the first month of pregnancy, which is before organogenesis; (ii) the second and third months of gestation, considered the most sensitive, and the so-called critical period for most major CAs; and (iii) the fourth to ninth months of gestation.']	organogenesis	GO_BP	[8664]	[8677]	PMC1252725_T129
PMC1252725	PMC1252725_53	[8497]	[8861]	['Gestational age was calculated from the first day of last menstrual period and three time intervals were considered: (i) the first month of pregnancy, which is before organogenesis; (ii) the second and third months of gestation, considered the most sensitive, and the so-called critical period for most major CAs; and (iii) the fourth to ninth months of gestation.']	gestation	GO_BP	[8715]	[8724]	PMC1252725_T130
PMC1252725	PMC1252725_53	[8497]	[8861]	['Gestational age was calculated from the first day of last menstrual period and three time intervals were considered: (i) the first month of pregnancy, which is before organogenesis; (ii) the second and third months of gestation, considered the most sensitive, and the so-called critical period for most major CAs; and (iii) the fourth to ninth months of gestation.']	gestation	GO_BP	[8851]	[8860]	PMC1252725_T131
PMC1252725	PMC1252725_54	[8862]	[9023]	['If pregnant women had infusion twice or more during the study pregnancy, only one treatment was analysed according to the following priority: 2-3, 1, 4-9 months.']	pregnant	GO_BP	[8865]	[8873]	PMC1252725_T132
PMC1252725	PMC1252725_54	[8862]	[9023]	['If pregnant women had infusion twice or more during the study pregnancy, only one treatment was analysed according to the following priority: 2-3, 1, 4-9 months.']	pregnancy	GO_BP	[8924]	[8933]	PMC1252725_T133
PMC1252725	PMC1252725_55	[9024]	[9144]	['Gestational age and birth weight were analysed in newborn infants of control mothers with or without infusion treatment.']	Gestational	GO_BP	[9024]	[9035]	PMC1252725_T134
PMC1252725	PMC1252725_55	[9024]	[9144]	['Gestational age and birth weight were analysed in newborn infants of control mothers with or without infusion treatment.']	birth	GO_BP	[9044]	[9049]	PMC1252725_T135
PMC1252725	PMC1252725_58	[9327]	[9523]	['Potential confounding factors, as maternal age, birth order, marital and employment status of mothers (as indicators of socioeconomic status), pregnancy complications and drug uses were evaluated.']	birth	GO_BP	[9375]	[9380]	PMC1252725_T136
PMC1252725	PMC1252725_58	[9327]	[9523]	['Potential confounding factors, as maternal age, birth order, marital and employment status of mothers (as indicators of socioeconomic status), pregnancy complications and drug uses were evaluated.']	pregnancy	GO_BP	[9470]	[9479]	PMC1252725_T137
PMC1252725	PMC1252725_58	[9327]	[9523]	['Potential confounding factors, as maternal age, birth order, marital and employment status of mothers (as indicators of socioeconomic status), pregnancy complications and drug uses were evaluated.']	drug	CHEBI	[9498]	[9502]	PMC1252725_T18
PMC1252725	PMC1252725_61	[9839]	[10041]	['Second, quantitative confounders such as maternal age, birth order, were compared using Student t test while POR with 95% CI were calculated for marital status and chi square test for employment status.']	birth	GO_BP	[9894]	[9899]	PMC1252725_T138
PMC1252725	PMC1252725_62	[10042]	[10162]	['Third, pregnancy complications were compared between case and control groups in unconditional logistic regression model.']	pregnancy	GO_BP	[10049]	[10058]	PMC1252725_T139
PMC1252725	PMC1252725_63	[10163]	[10279]	['Fourth, the distribution of gestational age according to the infusion treatment was evaluated using chi square test.']	gestational	GO_BP	[10191]	[10202]	PMC1252725_T140
PMC1252725	PMC1252725_66	[10742]	[11033]	['Finally, mean birth weight and gestational age of control newborn infants born to mothers with or without infusion treatment were compared in linear logistic regression model, while the proportion of preterm birth and low birthweight were compared in unconditional logistic regression model.']	birth	GO_BP	[10756]	[10761]	PMC1252725_T141
PMC1252725	PMC1252725_66	[10742]	[11033]	['Finally, mean birth weight and gestational age of control newborn infants born to mothers with or without infusion treatment were compared in linear logistic regression model, while the proportion of preterm birth and low birthweight were compared in unconditional logistic regression model.']	gestational	GO_BP	[10773]	[10784]	PMC1252725_T142
PMC1252725	PMC1252725_66	[10742]	[11033]	['Finally, mean birth weight and gestational age of control newborn infants born to mothers with or without infusion treatment were compared in linear logistic regression model, while the proportion of preterm birth and low birthweight were compared in unconditional logistic regression model.']	born	GO_BP	[10816]	[10820]	PMC1252725_T143
PMC1252725	PMC1252725_66	[10742]	[11033]	['Finally, mean birth weight and gestational age of control newborn infants born to mothers with or without infusion treatment were compared in linear logistic regression model, while the proportion of preterm birth and low birthweight were compared in unconditional logistic regression model.']	preterm	GO_BP	[10942]	[10949]	PMC1252725_T144
PMC1252725	PMC1252725_66	[10742]	[11033]	['Finally, mean birth weight and gestational age of control newborn infants born to mothers with or without infusion treatment were compared in linear logistic regression model, while the proportion of preterm birth and low birthweight were compared in unconditional logistic regression model.']	birth	GO_BP	[10950]	[10955]	PMC1252725_T145
PMC1252725	PMC1252725_66	[10742]	[11033]	['Finally, mean birth weight and gestational age of control newborn infants born to mothers with or without infusion treatment were compared in linear logistic regression model, while the proportion of preterm birth and low birthweight were compared in unconditional logistic regression model.']	birthweight	GO_BP	[10964]	[10975]	PMC1252725_T146
PMC1252725	PMC1252725_68	[11038]	[11177]	['Results\nDuring the study period, 2,146,574 babies were born in Hungary; therefore 38,151 controls represented 1.8% of the Hungarian births.']	born	GO_BP	[11093]	[11097]	PMC1252725_T147
PMC1252725	PMC1252725_68	[11038]	[11177]	['Results\nDuring the study period, 2,146,574 babies were born in Hungary; therefore 38,151 controls represented 1.8% of the Hungarian births.']	births	GO_BP	[11170]	[11176]	PMC1252725_T148
PMC1252725	PMC1252725_69	[11178]	[11240]	['In the control group, 262 (0.69%) pregnant women had infusion.']	pregnant	GO_BP	[11212]	[11220]	PMC1252725_T149
PMC1252725	PMC1252725_70	[11241]	[11369]	['The case group consisted of 22,843 malformed offspring and 112 (0.49%) pregnant women were treated by infusion during pregnancy.']	pregnant	GO_BP	[11312]	[11320]	PMC1252725_T150
PMC1252725	PMC1252725_70	[11241]	[11369]	['The case group consisted of 22,843 malformed offspring and 112 (0.49%) pregnant women were treated by infusion during pregnancy.']	pregnancy	GO_BP	[11359]	[11368]	PMC1252725_T151
PMC1252725	PMC1252725_73	[11587]	[11717]	['It is worth mentioning that pregnant women with infusion were younger with lower birth order than the mothers in the total groups.']	pregnant	GO_BP	[11615]	[11623]	PMC1252725_T152
PMC1252725	PMC1252725_73	[11587]	[11717]	['It is worth mentioning that pregnant women with infusion were younger with lower birth order than the mothers in the total groups.']	birth	GO_BP	[11668]	[11673]	PMC1252725_T153
PMC1252725	PMC1252725_74	[11718]	[11907]	['Mean maternal age did not show significant difference between case and control pregnant women with infusion, while the mean birth order was lower in the group of case mothers with infusion.']	pregnant	GO_BP	[11797]	[11805]	PMC1252725_T154
PMC1252725	PMC1252725_74	[11718]	[11907]	['Mean maternal age did not show significant difference between case and control pregnant women with infusion, while the mean birth order was lower in the group of case mothers with infusion.']	birth	GO_BP	[11842]	[11847]	PMC1252725_T155
PMC1252725	PMC1252725_76	[12070]	[12131]	['The prevalence of pregnancy complications is shown in Table2.']	pregnancy	GO_BP	[12088]	[12097]	PMC1252725_T156
PMC1252725	PMC1252725_77	[12132]	[12316]	['These data reflect the three main reasons of maternal infusion: (i) threatened preterm delivery in about half of mothers; (ii) hyperemesis gravidarum; and (iii) surgical interventions.']	preterm	GO_BP	[12211]	[12218]	PMC1252725_T157
PMC1252725	PMC1252725_77	[12132]	[12316]	['These data reflect the three main reasons of maternal infusion: (i) threatened preterm delivery in about half of mothers; (ii) hyperemesis gravidarum; and (iii) surgical interventions.']	delivery	GO_BP	[12219]	[12227]	PMC1252725_T158
PMC1252725	PMC1252725_77	[12132]	[12316]	['These data reflect the three main reasons of maternal infusion: (i) threatened preterm delivery in about half of mothers; (ii) hyperemesis gravidarum; and (iii) surgical interventions.']	hyperemesis	GO_BP	[12259]	[12270]	PMC1252725_T159
PMC1252725	PMC1252725_79	[12456]	[12596]	['However, there was no significant difference in the prevalence of pregnancy complications between the case and control groups with infusion.']	pregnancy	GO_BP	[12522]	[12531]	PMC1252725_T160
PMC1252725	PMC1252725_80	[12597]	[12713]	['The distribution of infusion according to the month of gestation in the case and controls groups is shown in Table3.']	gestation	GO_BP	[12652]	[12661]	PMC1252725_T161
PMC1252725	PMC1252725_82	[12759]	[12877]	['The first peak was connected with the treatment of hyperemesis gravidarum in the second and third months of gestation.']	hyperemesis	GO_BP	[12810]	[12821]	PMC1252725_T162
PMC1252725	PMC1252725_82	[12759]	[12877]	['The first peak was connected with the treatment of hyperemesis gravidarum in the second and third months of gestation.']	gestation	GO_BP	[12867]	[12876]	PMC1252725_T163
PMC1252725	PMC1252725_83	[12878]	[13024]	['The reason of second peak in the infusion treatments can be explained by threatened preterm delivery in the seventh and eighth month of gestation.']	preterm	GO_BP	[12962]	[12969]	PMC1252725_T164
PMC1252725	PMC1252725_83	[12878]	[13024]	['The reason of second peak in the infusion treatments can be explained by threatened preterm delivery in the seventh and eighth month of gestation.']	delivery	GO_BP	[12970]	[12978]	PMC1252725_T165
PMC1252725	PMC1252725_83	[12878]	[13024]	['The reason of second peak in the infusion treatments can be explained by threatened preterm delivery in the seventh and eighth month of gestation.']	gestation	GO_BP	[13014]	[13023]	PMC1252725_T166
PMC1252725	PMC1252725_84	[13025]	[13144]	['Mothers with surgical interventions are not evaluated here because these pregnant women were evaluated previously (10).']	pregnant	GO_BP	[13098]	[13106]	PMC1252725_T167
PMC1252725	PMC1252725_86	[13228]	[13446]	['There was no significant difference in the monthly distribution of infusions between controls and cases (χ28=7.55; p=0.48) and in the frequency of infusion during the second-third months of pregnancy (χ21=0.4; p=0.51).']	pregnancy	GO_BP	[13418]	[13427]	PMC1252725_T168
PMC1252725	PMC1252725_87	[13447]	[13599]	['The reason of infusion for hyperemesis gravidarum was fluid replacement combined with oral treatment of thiethylperazine, dimenhydrinate and vitamin B6.']	hyperemesis	GO_BP	[13474]	[13485]	PMC1252725_T169
PMC1252725	PMC1252725_87	[13447]	[13599]	['The reason of infusion for hyperemesis gravidarum was fluid replacement combined with oral treatment of thiethylperazine, dimenhydrinate and vitamin B6.']	thiethylperazine	CHEBI	[13551]	[13567]	PMC1252725_T19
PMC1252725	PMC1252725_87	[13447]	[13599]	['The reason of infusion for hyperemesis gravidarum was fluid replacement combined with oral treatment of thiethylperazine, dimenhydrinate and vitamin B6.']	dimenhydrinate	CHEBI	[13569]	[13583]	PMC1252725_T20
PMC1252725	PMC1252725_87	[13447]	[13599]	['The reason of infusion for hyperemesis gravidarum was fluid replacement combined with oral treatment of thiethylperazine, dimenhydrinate and vitamin B6.']	vitamin B6	CHEBI	[13588]	[13598]	PMC1252725_T21
PMC1252725	PMC1252725_88	[13600]	[14003]	['In general Saletanol D5®solution (sodium chloride 4.5 g, glucose 50 g and alcohol 50 g in 1000 ml solution with a speed of 30-40 drops/min which means 0.19/bw/hour of alcohol) or Ringer lactate®solution (sodium chloride 5.55 g, potassium chloride 0.3 g, calcium chloride 0.28 g, magnesium chloride 0.09 g, sodium lactate 5.04 g in 1000 ml with a speed of 120-150 drops/min) were used for this treatment.']	Saletanol	CHEBI	[13611]	[13620]	PMC1252725_T22
PMC1252725	PMC1252725_88	[13600]	[14003]	['In general Saletanol D5®solution (sodium chloride 4.5 g, glucose 50 g and alcohol 50 g in 1000 ml solution with a speed of 30-40 drops/min which means 0.19/bw/hour of alcohol) or Ringer lactate®solution (sodium chloride 5.55 g, potassium chloride 0.3 g, calcium chloride 0.28 g, magnesium chloride 0.09 g, sodium lactate 5.04 g in 1000 ml with a speed of 120-150 drops/min) were used for this treatment.']	solution	CHEBI	[13624]	[13632]	PMC1252725_T23
PMC1252725	PMC1252725_88	[13600]	[14003]	['In general Saletanol D5®solution (sodium chloride 4.5 g, glucose 50 g and alcohol 50 g in 1000 ml solution with a speed of 30-40 drops/min which means 0.19/bw/hour of alcohol) or Ringer lactate®solution (sodium chloride 5.55 g, potassium chloride 0.3 g, calcium chloride 0.28 g, magnesium chloride 0.09 g, sodium lactate 5.04 g in 1000 ml with a speed of 120-150 drops/min) were used for this treatment.']	sodium chloride	CHEBI	[13634]	[13649]	PMC1252725_T24
PMC1252725	PMC1252725_88	[13600]	[14003]	['In general Saletanol D5®solution (sodium chloride 4.5 g, glucose 50 g and alcohol 50 g in 1000 ml solution with a speed of 30-40 drops/min which means 0.19/bw/hour of alcohol) or Ringer lactate®solution (sodium chloride 5.55 g, potassium chloride 0.3 g, calcium chloride 0.28 g, magnesium chloride 0.09 g, sodium lactate 5.04 g in 1000 ml with a speed of 120-150 drops/min) were used for this treatment.']	glucose	CHEBI	[13657]	[13664]	PMC1252725_T25
PMC1252725	PMC1252725_88	[13600]	[14003]	['In general Saletanol D5®solution (sodium chloride 4.5 g, glucose 50 g and alcohol 50 g in 1000 ml solution with a speed of 30-40 drops/min which means 0.19/bw/hour of alcohol) or Ringer lactate®solution (sodium chloride 5.55 g, potassium chloride 0.3 g, calcium chloride 0.28 g, magnesium chloride 0.09 g, sodium lactate 5.04 g in 1000 ml with a speed of 120-150 drops/min) were used for this treatment.']	alcohol	CHEBI	[13674]	[13681]	PMC1252725_T26
PMC1252725	PMC1252725_88	[13600]	[14003]	['In general Saletanol D5®solution (sodium chloride 4.5 g, glucose 50 g and alcohol 50 g in 1000 ml solution with a speed of 30-40 drops/min which means 0.19/bw/hour of alcohol) or Ringer lactate®solution (sodium chloride 5.55 g, potassium chloride 0.3 g, calcium chloride 0.28 g, magnesium chloride 0.09 g, sodium lactate 5.04 g in 1000 ml with a speed of 120-150 drops/min) were used for this treatment.']	solution	CHEBI	[13698]	[13706]	PMC1252725_T27
PMC1252725	PMC1252725_88	[13600]	[14003]	['In general Saletanol D5®solution (sodium chloride 4.5 g, glucose 50 g and alcohol 50 g in 1000 ml solution with a speed of 30-40 drops/min which means 0.19/bw/hour of alcohol) or Ringer lactate®solution (sodium chloride 5.55 g, potassium chloride 0.3 g, calcium chloride 0.28 g, magnesium chloride 0.09 g, sodium lactate 5.04 g in 1000 ml with a speed of 120-150 drops/min) were used for this treatment.']	alcohol	CHEBI	[13767]	[13774]	PMC1252725_T28
PMC1252725	PMC1252725_88	[13600]	[14003]	['In general Saletanol D5®solution (sodium chloride 4.5 g, glucose 50 g and alcohol 50 g in 1000 ml solution with a speed of 30-40 drops/min which means 0.19/bw/hour of alcohol) or Ringer lactate®solution (sodium chloride 5.55 g, potassium chloride 0.3 g, calcium chloride 0.28 g, magnesium chloride 0.09 g, sodium lactate 5.04 g in 1000 ml with a speed of 120-150 drops/min) were used for this treatment.']	Ringer lactate	CHEBI	[13779]	[13793]	PMC1252725_T29
PMC1252725	PMC1252725_88	[13600]	[14003]	['In general Saletanol D5®solution (sodium chloride 4.5 g, glucose 50 g and alcohol 50 g in 1000 ml solution with a speed of 30-40 drops/min which means 0.19/bw/hour of alcohol) or Ringer lactate®solution (sodium chloride 5.55 g, potassium chloride 0.3 g, calcium chloride 0.28 g, magnesium chloride 0.09 g, sodium lactate 5.04 g in 1000 ml with a speed of 120-150 drops/min) were used for this treatment.']	solution	CHEBI	[13794]	[13802]	PMC1252725_T30
PMC1252725	PMC1252725_88	[13600]	[14003]	['In general Saletanol D5®solution (sodium chloride 4.5 g, glucose 50 g and alcohol 50 g in 1000 ml solution with a speed of 30-40 drops/min which means 0.19/bw/hour of alcohol) or Ringer lactate®solution (sodium chloride 5.55 g, potassium chloride 0.3 g, calcium chloride 0.28 g, magnesium chloride 0.09 g, sodium lactate 5.04 g in 1000 ml with a speed of 120-150 drops/min) were used for this treatment.']	sodium chloride	CHEBI	[13804]	[13819]	PMC1252725_T31
PMC1252725	PMC1252725_88	[13600]	[14003]	['In general Saletanol D5®solution (sodium chloride 4.5 g, glucose 50 g and alcohol 50 g in 1000 ml solution with a speed of 30-40 drops/min which means 0.19/bw/hour of alcohol) or Ringer lactate®solution (sodium chloride 5.55 g, potassium chloride 0.3 g, calcium chloride 0.28 g, magnesium chloride 0.09 g, sodium lactate 5.04 g in 1000 ml with a speed of 120-150 drops/min) were used for this treatment.']	potassium chloride	CHEBI	[13828]	[13846]	PMC1252725_T32
PMC1252725	PMC1252725_88	[13600]	[14003]	['In general Saletanol D5®solution (sodium chloride 4.5 g, glucose 50 g and alcohol 50 g in 1000 ml solution with a speed of 30-40 drops/min which means 0.19/bw/hour of alcohol) or Ringer lactate®solution (sodium chloride 5.55 g, potassium chloride 0.3 g, calcium chloride 0.28 g, magnesium chloride 0.09 g, sodium lactate 5.04 g in 1000 ml with a speed of 120-150 drops/min) were used for this treatment.']	calcium chloride	CHEBI	[13854]	[13870]	PMC1252725_T33
PMC1252725	PMC1252725_88	[13600]	[14003]	['In general Saletanol D5®solution (sodium chloride 4.5 g, glucose 50 g and alcohol 50 g in 1000 ml solution with a speed of 30-40 drops/min which means 0.19/bw/hour of alcohol) or Ringer lactate®solution (sodium chloride 5.55 g, potassium chloride 0.3 g, calcium chloride 0.28 g, magnesium chloride 0.09 g, sodium lactate 5.04 g in 1000 ml with a speed of 120-150 drops/min) were used for this treatment.']	magnesium chloride	CHEBI	[13879]	[13897]	PMC1252725_T34
PMC1252725	PMC1252725_88	[13600]	[14003]	['In general Saletanol D5®solution (sodium chloride 4.5 g, glucose 50 g and alcohol 50 g in 1000 ml solution with a speed of 30-40 drops/min which means 0.19/bw/hour of alcohol) or Ringer lactate®solution (sodium chloride 5.55 g, potassium chloride 0.3 g, calcium chloride 0.28 g, magnesium chloride 0.09 g, sodium lactate 5.04 g in 1000 ml with a speed of 120-150 drops/min) were used for this treatment.']	sodium lactate	CHEBI	[13906]	[13920]	PMC1252725_T35
PMC1252725	PMC1252725_89	[14004]	[14426]	['The reason of infusion for threatened preterm delivery was the so-called tocolysis, terbutaline (Bricanyl®) (5 mg per 1000 ml isotonic sodium chloride solution, 1 ml contains 5 μg for 8 h with a starting speed of 10 μg/min contained by 5 μg/min) and fenoterol (Partusisten®) (0.5 mg per 250-500 ml 5% glucose solution with a speed of 0.5-3.0 μg/min) were used for this purpose sometimes combined by verapamil (Verapamil®).']	preterm	GO_BP	[14042]	[14049]	PMC1252725_T170
PMC1252725	PMC1252725_89	[14004]	[14426]	['The reason of infusion for threatened preterm delivery was the so-called tocolysis, terbutaline (Bricanyl®) (5 mg per 1000 ml isotonic sodium chloride solution, 1 ml contains 5 μg for 8 h with a starting speed of 10 μg/min contained by 5 μg/min) and fenoterol (Partusisten®) (0.5 mg per 250-500 ml 5% glucose solution with a speed of 0.5-3.0 μg/min) were used for this purpose sometimes combined by verapamil (Verapamil®).']	delivery	GO_BP	[14050]	[14058]	PMC1252725_T171
PMC1252725	PMC1252725_89	[14004]	[14426]	['The reason of infusion for threatened preterm delivery was the so-called tocolysis, terbutaline (Bricanyl®) (5 mg per 1000 ml isotonic sodium chloride solution, 1 ml contains 5 μg for 8 h with a starting speed of 10 μg/min contained by 5 μg/min) and fenoterol (Partusisten®) (0.5 mg per 250-500 ml 5% glucose solution with a speed of 0.5-3.0 μg/min) were used for this purpose sometimes combined by verapamil (Verapamil®).']	terbutaline	CHEBI	[14088]	[14099]	PMC1252725_T36
PMC1252725	PMC1252725_89	[14004]	[14426]	['The reason of infusion for threatened preterm delivery was the so-called tocolysis, terbutaline (Bricanyl®) (5 mg per 1000 ml isotonic sodium chloride solution, 1 ml contains 5 μg for 8 h with a starting speed of 10 μg/min contained by 5 μg/min) and fenoterol (Partusisten®) (0.5 mg per 250-500 ml 5% glucose solution with a speed of 0.5-3.0 μg/min) were used for this purpose sometimes combined by verapamil (Verapamil®).']	Bricanyl	CHEBI	[14101]	[14109]	PMC1252725_T37
PMC1252725	PMC1252725_89	[14004]	[14426]	['The reason of infusion for threatened preterm delivery was the so-called tocolysis, terbutaline (Bricanyl®) (5 mg per 1000 ml isotonic sodium chloride solution, 1 ml contains 5 μg for 8 h with a starting speed of 10 μg/min contained by 5 μg/min) and fenoterol (Partusisten®) (0.5 mg per 250-500 ml 5% glucose solution with a speed of 0.5-3.0 μg/min) were used for this purpose sometimes combined by verapamil (Verapamil®).']	sodium chloride	CHEBI	[14139]	[14154]	PMC1252725_T38
PMC1252725	PMC1252725_89	[14004]	[14426]	['The reason of infusion for threatened preterm delivery was the so-called tocolysis, terbutaline (Bricanyl®) (5 mg per 1000 ml isotonic sodium chloride solution, 1 ml contains 5 μg for 8 h with a starting speed of 10 μg/min contained by 5 μg/min) and fenoterol (Partusisten®) (0.5 mg per 250-500 ml 5% glucose solution with a speed of 0.5-3.0 μg/min) were used for this purpose sometimes combined by verapamil (Verapamil®).']	solution	CHEBI	[14155]	[14163]	PMC1252725_T39
PMC1252725	PMC1252725_89	[14004]	[14426]	['The reason of infusion for threatened preterm delivery was the so-called tocolysis, terbutaline (Bricanyl®) (5 mg per 1000 ml isotonic sodium chloride solution, 1 ml contains 5 μg for 8 h with a starting speed of 10 μg/min contained by 5 μg/min) and fenoterol (Partusisten®) (0.5 mg per 250-500 ml 5% glucose solution with a speed of 0.5-3.0 μg/min) were used for this purpose sometimes combined by verapamil (Verapamil®).']	fenoterol	CHEBI	[14254]	[14263]	PMC1252725_T40
PMC1252725	PMC1252725_89	[14004]	[14426]	['The reason of infusion for threatened preterm delivery was the so-called tocolysis, terbutaline (Bricanyl®) (5 mg per 1000 ml isotonic sodium chloride solution, 1 ml contains 5 μg for 8 h with a starting speed of 10 μg/min contained by 5 μg/min) and fenoterol (Partusisten®) (0.5 mg per 250-500 ml 5% glucose solution with a speed of 0.5-3.0 μg/min) were used for this purpose sometimes combined by verapamil (Verapamil®).']	glucose	CHEBI	[14305]	[14312]	PMC1252725_T41
PMC1252725	PMC1252725_89	[14004]	[14426]	['The reason of infusion for threatened preterm delivery was the so-called tocolysis, terbutaline (Bricanyl®) (5 mg per 1000 ml isotonic sodium chloride solution, 1 ml contains 5 μg for 8 h with a starting speed of 10 μg/min contained by 5 μg/min) and fenoterol (Partusisten®) (0.5 mg per 250-500 ml 5% glucose solution with a speed of 0.5-3.0 μg/min) were used for this purpose sometimes combined by verapamil (Verapamil®).']	solution	CHEBI	[14313]	[14321]	PMC1252725_T42
PMC1252725	PMC1252725_89	[14004]	[14426]	['The reason of infusion for threatened preterm delivery was the so-called tocolysis, terbutaline (Bricanyl®) (5 mg per 1000 ml isotonic sodium chloride solution, 1 ml contains 5 μg for 8 h with a starting speed of 10 μg/min contained by 5 μg/min) and fenoterol (Partusisten®) (0.5 mg per 250-500 ml 5% glucose solution with a speed of 0.5-3.0 μg/min) were used for this purpose sometimes combined by verapamil (Verapamil®).']	verapamil	CHEBI	[14403]	[14412]	PMC1252725_T43
PMC1252725	PMC1252725_90	[14427]	[14504]	['The occurrence of other frequently used drugs (antibiotics, analgesics, etc.)']	drugs	CHEBI	[14467]	[14472]	PMC1252725_T44
PMC1252725	PMC1252725_90	[14427]	[14504]	['The occurrence of other frequently used drugs (antibiotics, analgesics, etc.)']	antibiotics	CHEBI	[14474]	[14485]	PMC1252725_T45
PMC1252725	PMC1252725_90	[14427]	[14504]	['The occurrence of other frequently used drugs (antibiotics, analgesics, etc.)']	analgesics	CHEBI	[14487]	[14497]	PMC1252725_T46
PMC1252725	PMC1252725_93	[14855]	[14944]	['There was no a higher prevalence of infusion during the study pregnancy in any CA-groups.']	pregnancy	GO_BP	[14917]	[14926]	PMC1252725_T172
PMC1252725	PMC1252725_94	[14945]	[15127]	['On the other hand the maternal infusion during the study pregnancy showed a lower occurrence in two CA‑groups: hypospadias and multiple CAs (which include heterogeneous CA-entities).']	pregnancy	GO_BP	[15002]	[15011]	PMC1252725_T173
PMC1252725	PMC1252725_96	[15247]	[15348]	['It is worth focusing the second and third months of gestation, the critical period of most major CAs.']	gestation	GO_BP	[15299]	[15308]	PMC1252725_T174
PMC1252725	PMC1252725_99	[15618]	[15853]	['This approach showed a higher adjusted POR with 95% CI for renal a/dysgenesis (4.4, 1.4-14.1), however, this possible association was based on 3 cases and two offspring had mothers with infusion after the third month of gestation (i.e.']	renal	UBERON	[15677]	[15682]	PMC1252725_T256
PMC1252725	PMC1252725_99	[15618]	[15853]	['This approach showed a higher adjusted POR with 95% CI for renal a/dysgenesis (4.4, 1.4-14.1), however, this possible association was based on 3 cases and two offspring had mothers with infusion after the third month of gestation (i.e.']	gestation	GO_BP	[15838]	[15847]	PMC1252725_T175
PMC1252725	PMC1252725_102	[16043]	[16124]	['The distribution of gestational age and birth weight groups and their mean ± S.D.']	gestational	GO_BP	[16063]	[16074]	PMC1252725_T176
PMC1252725	PMC1252725_102	[16043]	[16124]	['The distribution of gestational age and birth weight groups and their mean ± S.D.']	birth	GO_BP	[16083]	[16088]	PMC1252725_T177
PMC1252725	PMC1252725_103	[16125]	[16205]	['were evaluated only in control pregnant women with or without infusion (Table5).']	pregnant	GO_BP	[16156]	[16164]	PMC1252725_T178
PMC1252725	PMC1252725_104	[16206]	[16397]	['Both gestational age (adjusted t = 5.4, p<0.001) and birth weight (adjusted t = 7.6, p<0.001) were significantly lower in pregnant women with infusion than in pregnant women without infusion.']	gestational	GO_BP	[16211]	[16222]	PMC1252725_T179
PMC1252725	PMC1252725_104	[16206]	[16397]	['Both gestational age (adjusted t = 5.4, p<0.001) and birth weight (adjusted t = 7.6, p<0.001) were significantly lower in pregnant women with infusion than in pregnant women without infusion.']	birth	GO_BP	[16259]	[16264]	PMC1252725_T180
PMC1252725	PMC1252725_104	[16206]	[16397]	['Both gestational age (adjusted t = 5.4, p<0.001) and birth weight (adjusted t = 7.6, p<0.001) were significantly lower in pregnant women with infusion than in pregnant women without infusion.']	pregnant	GO_BP	[16328]	[16336]	PMC1252725_T181
PMC1252725	PMC1252725_104	[16206]	[16397]	['Both gestational age (adjusted t = 5.4, p<0.001) and birth weight (adjusted t = 7.6, p<0.001) were significantly lower in pregnant women with infusion than in pregnant women without infusion.']	pregnant	GO_BP	[16365]	[16373]	PMC1252725_T182
PMC1252725	PMC1252725_105	[16398]	[16569]	['These trends were in agreement with the higher rate of preterm birth (16.4% vs. 9.1%) and low birthweight (12.6% vs. 5.6%) of newborn infants born to mother with infusion.']	preterm birth	GO_BP	[16453]	[16466]	PMC1252725_T183
PMC1252725	PMC1252725_105	[16398]	[16569]	['These trends were in agreement with the higher rate of preterm birth (16.4% vs. 9.1%) and low birthweight (12.6% vs. 5.6%) of newborn infants born to mother with infusion.']	birthweight	GO_BP	[16492]	[16503]	PMC1252725_T184
PMC1252725	PMC1252725_105	[16398]	[16569]	['These trends were in agreement with the higher rate of preterm birth (16.4% vs. 9.1%) and low birthweight (12.6% vs. 5.6%) of newborn infants born to mother with infusion.']	born	GO_BP	[16540]	[16544]	PMC1252725_T185
PMC1252725	PMC1252725_106	[16570]	[16834]	['These differences were more obvious in women who had infusion in the sixth-ninth month of gestation: mean gestational age was 38.1 ± 2.6 and 39.4 ± 2.0 week, while mean birth weight 2,941 ± 529 and 3,277 ± 311 gram in women with and without infusion, respectively.']	gestation	GO_BP	[16660]	[16669]	PMC1252725_T186
PMC1252725	PMC1252725_106	[16570]	[16834]	['These differences were more obvious in women who had infusion in the sixth-ninth month of gestation: mean gestational age was 38.1 ± 2.6 and 39.4 ± 2.0 week, while mean birth weight 2,941 ± 529 and 3,277 ± 311 gram in women with and without infusion, respectively.']	gestational	GO_BP	[16676]	[16687]	PMC1252725_T187
PMC1252725	PMC1252725_106	[16570]	[16834]	['These differences were more obvious in women who had infusion in the sixth-ninth month of gestation: mean gestational age was 38.1 ± 2.6 and 39.4 ± 2.0 week, while mean birth weight 2,941 ± 529 and 3,277 ± 311 gram in women with and without infusion, respectively.']	birth	GO_BP	[16739]	[16744]	PMC1252725_T188
PMC1252725	PMC1252725_107	[16835]	[17031]	['On the other hand the mean gestational age (39.4 ± 2.5 vs. 39.4 ± 2.0 week) in control women with or without infusion was similar between the second and fifth months due to hyperemesis gravidarum.']	gestational	GO_BP	[16862]	[16873]	PMC1252725_T189
PMC1252725	PMC1252725_108	[17032]	[17211]	['However, there was a significant reduction in mean birth weight (3,162 ± 596 vs. 3,276 ± 511 gram) and it was reflected in a higher proportion of low birthweight (10.4% vs. 5.7%).']	birth	GO_BP	[17083]	[17088]	PMC1252725_T190
PMC1252725	PMC1252725_108	[17032]	[17211]	['However, there was a significant reduction in mean birth weight (3,162 ± 596 vs. 3,276 ± 511 gram) and it was reflected in a higher proportion of low birthweight (10.4% vs. 5.7%).']	birthweight	GO_BP	[17182]	[17193]	PMC1252725_T191
PMC1252725	PMC1252725_110	[17216]	[17415]	['Discussion\nOur study is the first to evaluate the possible association in general between the effect of maternal infusion treatments during pregnancy and the different variables of fetal development.']	pregnancy	GO_BP	[17356]	[17365]	PMC1252725_T192
PMC1252725	PMC1252725_110	[17216]	[17415]	['Discussion\nOur study is the first to evaluate the possible association in general between the effect of maternal infusion treatments during pregnancy and the different variables of fetal development.']	fetal development	GO_BP	[17397]	[17414]	PMC1252725_T193
PMC1252725	PMC1252725_112	[17560]	[17658]	['Thus, we were not able to detect any teratogenic potential of infusion treatment during pregnancy.']	teratogenic	CHEBI	[17597]	[17608]	PMC1252725_T47
PMC1252725	PMC1252725_112	[17560]	[17658]	['Thus, we were not able to detect any teratogenic potential of infusion treatment during pregnancy.']	teratogenic	GO_BP	[17597]	[17608]	PMC1252725_T194
PMC1252725	PMC1252725_112	[17560]	[17658]	['Thus, we were not able to detect any teratogenic potential of infusion treatment during pregnancy.']	pregnancy	GO_BP	[17648]	[17657]	PMC1252725_T195
PMC1252725	PMC1252725_113	[17659]	[17907]	['On the other hand, mean gestational age was shorter and mean birth weight was smaller in control newborn infants without CA born to mothers with infusion treatment during the study pregnancy than in the babies of mothers without infusion treatment.']	gestational	GO_BP	[17683]	[17694]	PMC1252725_T196
PMC1252725	PMC1252725_113	[17659]	[17907]	['On the other hand, mean gestational age was shorter and mean birth weight was smaller in control newborn infants without CA born to mothers with infusion treatment during the study pregnancy than in the babies of mothers without infusion treatment.']	birth	GO_BP	[17720]	[17725]	PMC1252725_T197
PMC1252725	PMC1252725_113	[17659]	[17907]	['On the other hand, mean gestational age was shorter and mean birth weight was smaller in control newborn infants without CA born to mothers with infusion treatment during the study pregnancy than in the babies of mothers without infusion treatment.']	CA	CHEBI	[17780]	[17782]	PMC1252725_T48
PMC1252725	PMC1252725_113	[17659]	[17907]	['On the other hand, mean gestational age was shorter and mean birth weight was smaller in control newborn infants without CA born to mothers with infusion treatment during the study pregnancy than in the babies of mothers without infusion treatment.']	born	GO_BP	[17783]	[17787]	PMC1252725_T198
PMC1252725	PMC1252725_113	[17659]	[17907]	['On the other hand, mean gestational age was shorter and mean birth weight was smaller in control newborn infants without CA born to mothers with infusion treatment during the study pregnancy than in the babies of mothers without infusion treatment.']	pregnancy	GO_BP	[17840]	[17849]	PMC1252725_T199
PMC1252725	PMC1252725_114	[17908]	[18020]	['Thus, infusion of drugs used for the prevention of threatened preterm delivery seems to have a limited efficacy.']	drugs	CHEBI	[17926]	[17931]	PMC1252725_T49
PMC1252725	PMC1252725_114	[17908]	[18020]	['Thus, infusion of drugs used for the prevention of threatened preterm delivery seems to have a limited efficacy.']	preterm	GO_BP	[17970]	[17977]	PMC1252725_T200
PMC1252725	PMC1252725_114	[17908]	[18020]	['Thus, infusion of drugs used for the prevention of threatened preterm delivery seems to have a limited efficacy.']	delivery	GO_BP	[17978]	[17986]	PMC1252725_T201
PMC1252725	PMC1252725_115	[18021]	[18276]	['However, the ratio of threatened preterm delivery was 1 in 3.6 among pregnancy complications instead of the ratio of preterm birth: 1 in 1.8, therefore nearly half of threatened preterm deliveries was effectively treated, therefore it was not inefficient.']	preterm delivery	GO_BP	[18054]	[18070]	PMC1252725_T202
PMC1252725	PMC1252725_115	[18021]	[18276]	['However, the ratio of threatened preterm delivery was 1 in 3.6 among pregnancy complications instead of the ratio of preterm birth: 1 in 1.8, therefore nearly half of threatened preterm deliveries was effectively treated, therefore it was not inefficient.']	pregnancy	GO_BP	[18090]	[18099]	PMC1252725_T203
PMC1252725	PMC1252725_115	[18021]	[18276]	['However, the ratio of threatened preterm delivery was 1 in 3.6 among pregnancy complications instead of the ratio of preterm birth: 1 in 1.8, therefore nearly half of threatened preterm deliveries was effectively treated, therefore it was not inefficient.']	preterm birth	GO_BP	[18138]	[18151]	PMC1252725_T204
PMC1252725	PMC1252725_115	[18021]	[18276]	['However, the ratio of threatened preterm delivery was 1 in 3.6 among pregnancy complications instead of the ratio of preterm birth: 1 in 1.8, therefore nearly half of threatened preterm deliveries was effectively treated, therefore it was not inefficient.']	preterm	GO_BP	[18199]	[18206]	PMC1252725_T205
PMC1252725	PMC1252725_115	[18021]	[18276]	['However, the ratio of threatened preterm delivery was 1 in 3.6 among pregnancy complications instead of the ratio of preterm birth: 1 in 1.8, therefore nearly half of threatened preterm deliveries was effectively treated, therefore it was not inefficient.']	deliveries	GO_BP	[18207]	[18217]	PMC1252725_T206
PMC1252725	PMC1252725_116	[18277]	[18434]	['In addition, intrauterine growth retardation was found in newborn infants born to mothers with hyperemesis gravidarum on the contrary of infusion treatments.']	intrauterine	UBERON	[18290]	[18302]	PMC1252725_T257
PMC1252725	PMC1252725_116	[18277]	[18434]	['In addition, intrauterine growth retardation was found in newborn infants born to mothers with hyperemesis gravidarum on the contrary of infusion treatments.']	born	GO_BP	[18351]	[18355]	PMC1252725_T207
PMC1252725	PMC1252725_116	[18277]	[18434]	['In addition, intrauterine growth retardation was found in newborn infants born to mothers with hyperemesis gravidarum on the contrary of infusion treatments.']	hyperemesis	GO_BP	[18372]	[18383]	PMC1252725_T208
PMC1252725	PMC1252725_117	[18435]	[18645]	["The strengths of the HCCSCA's data set are (i) the large and (ii) population-based cohort including 374 pregnant women with infusion treatment (iii) in an ethnically homogeneous European (Caucasian) population."]	pregnant	GO_BP	[18539]	[18547]	PMC1252725_T209
PMC1252725	PMC1252725_119	[18759]	[19025]	['(v) Cases with CA and their controls without CAs were matched, (vi) main confounders were known, (vii) birth weight and gestational age were medically recorded, and (viii) there was a good validity of CA-diagnoses due to the results of recent medical examinations14.']	birth	GO_BP	[18862]	[18867]	PMC1252725_T210
PMC1252725	PMC1252725_119	[18759]	[19025]	['(v) Cases with CA and their controls without CAs were matched, (vi) main confounders were known, (vii) birth weight and gestational age were medically recorded, and (viii) there was a good validity of CA-diagnoses due to the results of recent medical examinations14.']	gestational	GO_BP	[18879]	[18890]	PMC1252725_T211
PMC1252725	PMC1252725_123	[19273]	[19420]	['However, the use of drugs in control mothers with no response did not differ significantly from the rate of control pregnant women who responded16.']	drugs	CHEBI	[19293]	[19298]	PMC1252725_T50
PMC1252725	PMC1252725_123	[19273]	[19420]	['However, the use of drugs in control mothers with no response did not differ significantly from the rate of control pregnant women who responded16.']	pregnant	GO_BP	[19389]	[19397]	PMC1252725_T212
PMC1252725	PMC1252725_124	[19421]	[19702]	['Multiple comparison may produce a statistically significant association (p<0.05) in every 20thestimation because of chance and we explain the higher occurrence of renal a/dysgenesis after infusion treatment at the comparison of this CA group with the total control group by chance.']	renal	UBERON	[19584]	[19589]	PMC1252725_T258
PMC1252725	PMC1252725_125	[19703]	[19857]	['In addition this possible association was based on 3 cases because only one was born to the mother who had infusion in the second month of gestation, i.e.']	born	GO_BP	[19783]	[19787]	PMC1252725_T213
PMC1252725	PMC1252725_125	[19703]	[19857]	['In addition this possible association was based on 3 cases because only one was born to the mother who had infusion in the second month of gestation, i.e.']	gestation	GO_BP	[19842]	[19851]	PMC1252725_T214
PMC1252725	PMC1252725_126	[19858]	[19907]	['during the critical period of renal a/dysgenesis.']	renal	UBERON	[19888]	[19893]	PMC1252725_T259
PMC1252725	PMC1252725_127	[19908]	[20004]	['The type of drugs obviously has a greater impact for fetuses than the route of administration17.']	drugs	CHEBI	[19920]	[19925]	PMC1252725_T51
PMC1252725	PMC1252725_128	[20005]	[20159]	['Thus it is not possible to evaluate the impact of an administration route (namely infusion in this study) without taking into account the different drugs.']	drugs	CHEBI	[20153]	[20158]	PMC1252725_T52
PMC1252725	PMC1252725_129	[20160]	[20269]	['However, the major reason of infusion in pregnant women with hyperemesis gravidarum is the fluid replacement.']	pregnant	GO_BP	[20201]	[20209]	PMC1252725_T215
PMC1252725	PMC1252725_129	[20160]	[20269]	['However, the major reason of infusion in pregnant women with hyperemesis gravidarum is the fluid replacement.']	fluid	CHEBI	[20251]	[20256]	PMC1252725_T53
PMC1252725	PMC1252725_129	[20160]	[20269]	['However, the major reason of infusion in pregnant women with hyperemesis gravidarum is the fluid replacement.']	fluid	UBERON	[20251]	[20256]	PMC1252725_T260
PMC1252725	PMC1252725_130	[20270]	[20380]	['The teratogenic potential of antiemetic drugs used in Hungary parallel with infusion was evaluated previously.']	teratogenic	CHEBI	[20274]	[20285]	PMC1252725_T54
PMC1252725	PMC1252725_130	[20270]	[20380]	['The teratogenic potential of antiemetic drugs used in Hungary parallel with infusion was evaluated previously.']	teratogenic	GO_BP	[20274]	[20285]	PMC1252725_T216
PMC1252725	PMC1252725_130	[20270]	[20380]	['The teratogenic potential of antiemetic drugs used in Hungary parallel with infusion was evaluated previously.']	antiemetic drugs	CHEBI	[20299]	[20315]	PMC1252725_T55
PMC1252725	PMC1252725_131	[20381]	[20586]	['A weak association was found between thiethylperazine and cleft lip ± palate18, there was no teratogenic potential of dimenhydrinate19, while vitamin B6 showed a protective effect for cardiovascular CAs20.']	thiethylperazine	CHEBI	[20418]	[20434]	PMC1252725_T56
PMC1252725	PMC1252725_131	[20381]	[20586]	['A weak association was found between thiethylperazine and cleft lip ± palate18, there was no teratogenic potential of dimenhydrinate19, while vitamin B6 showed a protective effect for cardiovascular CAs20.']	teratogenic	CHEBI	[20474]	[20485]	PMC1252725_T57
PMC1252725	PMC1252725_131	[20381]	[20586]	['A weak association was found between thiethylperazine and cleft lip ± palate18, there was no teratogenic potential of dimenhydrinate19, while vitamin B6 showed a protective effect for cardiovascular CAs20.']	vitamin B6	CHEBI	[20523]	[20533]	PMC1252725_T58
PMC1252725	PMC1252725_132	[20587]	[20727]	['The other main indication of infusion therapy was threatened preterm delivery and it was combined with terbutaline, fenoterol and verapamil.']	preterm	GO_BP	[20648]	[20655]	PMC1252725_T217
PMC1252725	PMC1252725_132	[20587]	[20727]	['The other main indication of infusion therapy was threatened preterm delivery and it was combined with terbutaline, fenoterol and verapamil.']	delivery	GO_BP	[20656]	[20664]	PMC1252725_T218
PMC1252725	PMC1252725_132	[20587]	[20727]	['The other main indication of infusion therapy was threatened preterm delivery and it was combined with terbutaline, fenoterol and verapamil.']	terbutaline	CHEBI	[20690]	[20701]	PMC1252725_T59
PMC1252725	PMC1252725_132	[20587]	[20727]	['The other main indication of infusion therapy was threatened preterm delivery and it was combined with terbutaline, fenoterol and verapamil.']	fenoterol	CHEBI	[20703]	[20712]	PMC1252725_T60
PMC1252725	PMC1252725_133	[20728]	[20807]	['In general the time of this treatment was the last trimester of pregnancy (i.e.']	trimester	GO_BP	[20779]	[20788]	PMC1252725_T219
PMC1252725	PMC1252725_133	[20728]	[20807]	['In general the time of this treatment was the last trimester of pregnancy (i.e.']	pregnancy	GO_BP	[20792]	[20801]	PMC1252725_T220
PMC1252725	PMC1252725_134	[20808]	[20833]	['after the organogenesis).']	organogenesis	GO_BP	[20818]	[20831]	PMC1252725_T221
PMC1252725	PMC1252725_135	[20834]	[20965]	['We need further studies to evaluate in general the efficacy of different drugs according to administration route in pregnant women.']	drugs	CHEBI	[20907]	[20912]	PMC1252725_T61
PMC1252725	PMC1252725_135	[20834]	[20965]	['We need further studies to evaluate in general the efficacy of different drugs according to administration route in pregnant women.']	pregnant	GO_BP	[20950]	[20958]	PMC1252725_T222
PMC1252725	PMC1252725_136	[20966]	[21131]	['The intravenous route is used for the administration of medications when immediate or special drug action is required due to the severity of pathological conditions.']	medications	CHEBI	[21022]	[21033]	PMC1252725_T62
PMC1252725	PMC1252725_136	[20966]	[21131]	['The intravenous route is used for the administration of medications when immediate or special drug action is required due to the severity of pathological conditions.']	drug	CHEBI	[21060]	[21064]	PMC1252725_T63
PMC1252725	PMC1252725_137	[21132]	[21258]	['Nevertheless, a teratogenic potential of infusion treatment and/or drugs, in addition underlying pregnancy complications (e.g.']	teratogenic	GO_BP	[21148]	[21159]	PMC1252725_T223
PMC1252725	PMC1252725_137	[21132]	[21258]	['Nevertheless, a teratogenic potential of infusion treatment and/or drugs, in addition underlying pregnancy complications (e.g.']	drugs	CHEBI	[21199]	[21204]	PMC1252725_T64
PMC1252725	PMC1252725_137	[21132]	[21258]	['Nevertheless, a teratogenic potential of infusion treatment and/or drugs, in addition underlying pregnancy complications (e.g.']	pregnancy	GO_BP	[21229]	[21238]	PMC1252725_T224
PMC1252725	PMC1252725_138	[21259]	[21321]	['dehydration) during pregnancy was not detectable in our study.']	pregnancy	GO_BP	[21279]	[21288]	PMC1252725_T225
PMC1252725	PMC1252725_139	[21322]	[21436]	['The dehydration in experimental animal (mouse) investigations caused CAs, particularly isolated cleft palate21,22.']	animal	NCBITAXON	[21354]	[21360]	PMC1252725_T241
PMC1252725	PMC1252725_139	[21322]	[21436]	['The dehydration in experimental animal (mouse) investigations caused CAs, particularly isolated cleft palate21,22.']	mouse	NCBITAXON	[21362]	[21367]	PMC1252725_T242
PMC1252725	PMC1252725_140	[21437]	[21553]	['In fact, mothers who had infusion treatment later delivered boys with a lower risk for hypospadias and multiple CAs.']	delivered	GO_BP	[21487]	[21496]	PMC1252725_T226
PMC1252725	PMC1252725_142	[21602]	[21748]	['The gestational age was shorter and birth weight was lower in control infants without CA born to mothers with infusion treatment during pregnancy.']	gestational	GO_BP	[21606]	[21617]	PMC1252725_T227
PMC1252725	PMC1252725_142	[21602]	[21748]	['The gestational age was shorter and birth weight was lower in control infants without CA born to mothers with infusion treatment during pregnancy.']	birth	GO_BP	[21638]	[21643]	PMC1252725_T228
PMC1252725	PMC1252725_142	[21602]	[21748]	['The gestational age was shorter and birth weight was lower in control infants without CA born to mothers with infusion treatment during pregnancy.']	born	GO_BP	[21691]	[21695]	PMC1252725_T229
PMC1252725	PMC1252725_142	[21602]	[21748]	['The gestational age was shorter and birth weight was lower in control infants without CA born to mothers with infusion treatment during pregnancy.']	pregnancy	GO_BP	[21738]	[21747]	PMC1252725_T230
PMC1252725	PMC1252725_143	[21749]	[21902]	['These findings may indicate the limited value of this treatment because these pregnant women had also a significantly higher proportion of preterm birth.']	pregnant	GO_BP	[21827]	[21835]	PMC1252725_T231
PMC1252725	PMC1252725_143	[21749]	[21902]	['These findings may indicate the limited value of this treatment because these pregnant women had also a significantly higher proportion of preterm birth.']	preterm birth	GO_BP	[21888]	[21901]	PMC1252725_T232
PMC1252725	PMC1252725_144	[21903]	[22044]	['In addition, babies born to mothers with hyperemesis gravidarum showed intrauterine growth retardation on the contrary of infusion treatment.']	born	GO_BP	[21923]	[21927]	PMC1252725_T233
PMC1252725	PMC1252725_144	[21903]	[22044]	['In addition, babies born to mothers with hyperemesis gravidarum showed intrauterine growth retardation on the contrary of infusion treatment.']	hyperemesis	GO_BP	[21944]	[21955]	PMC1252725_T234
PMC1252725	PMC1252725_144	[21903]	[22044]	['In addition, babies born to mothers with hyperemesis gravidarum showed intrauterine growth retardation on the contrary of infusion treatment.']	intrauterine	UBERON	[21974]	[21986]	PMC1252725_T261
PMC1252725	PMC1252725_145	[22045]	[22137]	['Similar findings were not found in women with severe nausea and vomiting during pregnancy23.']	pregnancy23	GO_BP	[22125]	[22136]	PMC1252725_T235
PMC1252725	PMC1252725_146	[22138]	[22273]	['In conclusion, the results of our study suggest that infusion treatment of pregnant women did not associate with a higher risk for CAs.']	pregnant	GO_BP	[22213]	[22221]	PMC1252725_T236
PMC1252725	PMC1252725_147	[22274]	[22428]	['The intravenous infusion of drugs have some, but limited efficacy to prevent the adverse effect of hyperemesis gravidarum and threatened preterm delivery.']	drugs	CHEBI	[22302]	[22307]	PMC1252725_T65
PMC1252725	PMC1252725_147	[22274]	[22428]	['The intravenous infusion of drugs have some, but limited efficacy to prevent the adverse effect of hyperemesis gravidarum and threatened preterm delivery.']	hyperemesis	GO_BP	[22373]	[22384]	PMC1252725_T237
PMC1252725	PMC1252725_147	[22274]	[22428]	['The intravenous infusion of drugs have some, but limited efficacy to prevent the adverse effect of hyperemesis gravidarum and threatened preterm delivery.']	preterm	GO_BP	[22411]	[22418]	PMC1252725_T238
PMC1252725	PMC1252725_147	[22274]	[22428]	['The intravenous infusion of drugs have some, but limited efficacy to prevent the adverse effect of hyperemesis gravidarum and threatened preterm delivery.']	delivery	GO_BP	[22419]	[22427]	PMC1252725_T239
PMC1252725	PMC1252725_150	[22499]	[22631]	['Reproduction is permitted for personal and noncommerical use, provided that the article is in whole, unmodified, and properly cited.']	Reproduction	GO_BP	[22499]	[22511]	PMC1252725_T240
